Bavarian Nordic and BioNTech are two interesting companies in the field of Mpox vaccines. Bavarian Nordic offers the only licensed vaccine (MVA-BN) and is expanding globally to meet the growing demand. BioNTech, on the other hand, is developing an mRNA vaccine that could ensure flexible and rapid production thanks to its technology. $BAVA (+0,39 %)
$BNTX (-0,18 %)

Bavarian Nordic has proven products, while BioNTech could convince through innovation. Both companies offer a lot of potential, but which approach is more successful in the long term? What do you think?